Qiong Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qiong Dong has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Catherine A. Wassenaar
Department of Pharmacology & Toxicology, University of Toronto, 1 King’s College Circle, Toronto, M5S 1A8ON, Canada
1 shared publication - Christopher I. Amos
The University of Texas MD Anderson Cancer Center, Houston, TX
1 shared publication - Christopher I. Amos
Biomedical Data Science Department, Dartmouth College, Hanover, NH, USA
1 shared publication - Margaret R. Spitz
Department of Epidemiology, Unit 1340, The University of Texas M. D. Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230-1439, USA
1 shared publication - Margaret R. Spitz
Baylor College of Medicine, Houston, TX, USA
1 shared publication - Peng Wei
The University of Texas MD Anderson Cancer Center
1 shared publication
Latest Publications
- Open Access
- 16 April 2013
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (4) , 8381-8392
Pilot Study of CYP2B6 Genetic Variation to Explore the Contribution of Nitrosamine Activation to Lung Carcinogenesis
We explored the contribution of nitrosamine metabolism to lung cancer in a pilot investigation of genetic variation in CYP2B6, a high-affinity enzymatic activator of tobacco-specific nitrosamines with a negligible role in nicotine metabolism. Previously we found that variation in CYP2A6 and CHRNA5-CHRNA3-CHRNB4 combined to increase lung cancer risk in a case-control study in European American ever-smokers (n = 860). However, these genes are involved in the pharmacology of both nicotine, through which they alter smoking behaviours, and carcinogenic nitrosamines. Herein, we separated participants by CYP2B6 genotype into a high- vs. low-risk group (*1/*1 + *1/*6 vs. *6/*6). Odds ratios estimated through logistic regression modeling were 1.25 (95% CI 0.68–2.30), 1.27 (95% CI 0.89–1.79) and 1.56 (95% CI 1.04–2.31) for CYP2B6, CYP2A6 and CHRNA5-CHRNA3-CHRNB4, respectively, with negligible differences when all genes were evaluated concurrently. Modeling the combined impact of high-risk genotypes yielded odds ratios that rose from 2.05 (95% CI 0.39–10.9) to 2.43 (95% CI 0.47–12.7) to 3.94 (95% CI 0.72–21.5) for those with 1, 2 and 3 vs. 0 high-risk genotypes, respectively. Findings from this pilot point to genetic variation in CYP2B6 as a lung cancer risk factor supporting a role for nitrosamine metabolic activation in the molecular mechanism of lung carcinogenesis
- 16 April 2013
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (4) , 8381-8392
Open AccessPilot Study of CYP2B6 Genetic Variation to Explore the Contribution of Nitrosamine Activation to Lung Carcinogenesis
We explored the contribution of nitrosamine metabolism to lung cancer in a pilot investigation of genetic variation in CYP2B6, a high-affinity enzymatic activator of tobacco-specific nitrosamines with a negligible role in nicotine metabolism. Previously we found that variation in CYP2A6 and CHRNA5-CHRNA3-CHRNB4 combined to increase lung cancer risk in a case-control study in European American ever-smokers (n = 860). However, these genes are involved in the pharmacology of both nicotine, through which they alter smoking behaviours, and carcinogenic nitrosamines. Herein, we separated participants by CYP2B6 genotype into a high- vs. low-risk group (*1/*1 + *1/*6 vs. *6/*6). Odds ratios estimated through logistic regression modeling were 1.25 (95% CI 0.68–2.30), 1.27 (95% CI 0.89–1.79) and 1.56 (95% CI 1.04–2.31) for CYP2B6, CYP2A6 and CHRNA5-CHRNA3-CHRNB4, respectively, with negligible differences when all genes were evaluated concurrently. Modeling the combined impact of high-risk genotypes yielded odds ratios that rose from 2.05 (95% CI 0.39–10.9) to 2.43 (95% CI 0.47–12.7) to 3.94 (95% CI 0.72–21.5) for those with 1, 2 and 3 vs. 0 high-risk genotypes, respectively. Findings from this pilot point to genetic variation in CYP2B6 as a lung cancer risk factor supporting a role for nitrosamine metabolic activation in the molecular mechanism of lung carcinogenesis
- 1 August 2003
- Vol. 12 (8) , 689-98
Genetic susceptibility to lung cancer: the role of DNA damage and repair.
- 1 August 2003
- Vol. 12 (8) , 689-98
Genetic susceptibility to lung cancer: the role of DNA damage and repair.